Shionogi (4507) Stock Overview

Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. More details

4507 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance3/6
Financial Health6/6
Dividends5/6

4507 Community Fair Values

Create Narrative

See what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.

Shionogi & Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Shionogi
Historical stock prices
Current Share PriceJP¥2,476.00
52 Week HighJP¥2,616.00
52 Week LowJP¥1,944.67
Beta0.10
1 Month Change-1.30%
3 Month Change4.61%
1 Year Change12.12%
3 Year Change-1.49%
5 Year Change16.59%
Change since IPO687.70%

Recent News & Updates

Recent updates

Analysts Are Updating Their Shionogi & Co., Ltd. (TSE:4507) Estimates After Its Full-Year Results

May 14
Analysts Are Updating Their Shionogi & Co., Ltd. (TSE:4507) Estimates After Its Full-Year Results

There's Reason For Concern Over Shionogi & Co., Ltd.'s (TSE:4507) Price

Mar 23
There's Reason For Concern Over Shionogi & Co., Ltd.'s (TSE:4507) Price

Is There An Opportunity With Shionogi & Co., Ltd.'s (TSE:4507) 50% Undervaluation?

Mar 01
Is There An Opportunity With Shionogi & Co., Ltd.'s (TSE:4507) 50% Undervaluation?

We Think Shionogi's (TSE:4507) Healthy Earnings Might Be Conservative

Feb 07
We Think Shionogi's (TSE:4507) Healthy Earnings Might Be Conservative

Shionogi & Co., Ltd. Just Recorded A 34% EPS Beat: Here's What Analysts Are Forecasting Next

Feb 04
Shionogi & Co., Ltd. Just Recorded A 34% EPS Beat: Here's What Analysts Are Forecasting Next

There's Reason For Concern Over Shionogi & Co., Ltd.'s (TSE:4507) Price

Nov 26
There's Reason For Concern Over Shionogi & Co., Ltd.'s (TSE:4507) Price

Shionogi & Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next

Oct 30
Shionogi & Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next

Shionogi's (TSE:4507) Dividend Will Be ¥85.00

Sep 11
Shionogi's (TSE:4507) Dividend Will Be ¥85.00

Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00

Aug 28
Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00

Shionogi's (TSE:4507) Dividend Will Be ¥85.00

Aug 09
Shionogi's (TSE:4507) Dividend Will Be ¥85.00

Shionogi & Co., Ltd. Just Missed EPS By 20%: Here's What Analysts Think Will Happen Next

Jul 31
Shionogi & Co., Ltd. Just Missed EPS By 20%: Here's What Analysts Think Will Happen Next

Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00

Jul 26
Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00

Shareholder Returns

4507JP PharmaceuticalsJP Market
7D0.4%2.1%0.3%
1Y12.1%-11.1%-2.1%

Return vs Industry: 4507 exceeded the JP Pharmaceuticals industry which returned -11.1% over the past year.

Return vs Market: 4507 exceeded the JP Market which returned -2.1% over the past year.

Price Volatility

Is 4507's price volatile compared to industry and market?
4507 volatility
4507 Average Weekly Movement3.3%
Pharmaceuticals Industry Average Movement4.5%
Market Average Movement3.6%
10% most volatile stocks in JP Market7.5%
10% least volatile stocks in JP Market1.8%

Stable Share Price: 4507 has not had significant price volatility in the past 3 months compared to the JP market.

Volatility Over Time: 4507's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
18784,955Isao Teshirogiwww.shionogi.com

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19.

Shionogi & Co., Ltd. Fundamentals Summary

How do Shionogi's earnings and revenue compare to its market cap?
4507 fundamental statistics
Market capJP¥2.12t
Earnings (TTM)JP¥170.44b
Revenue (TTM)JP¥438.27b
12.4x
P/E Ratio
4.8x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4507 income statement (TTM)
RevenueJP¥438.27b
Cost of RevenueJP¥63.83b
Gross ProfitJP¥374.44b
Other ExpensesJP¥204.01b
EarningsJP¥170.44b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Jul 28, 2025

Earnings per share (EPS)200.35
Gross Margin85.44%
Net Profit Margin38.89%
Debt/Equity Ratio0%

How did 4507 perform over the long term?

See historical performance and comparison

Dividends

2.7%
Current Dividend Yield
29%
Payout Ratio

Does 4507 pay a reliable dividends?

See 4507 dividend history and benchmarks
When do you need to buy 4507 by to receive an upcoming dividend?
Shionogi dividend dates
Ex Dividend DateSep 29 2025
Dividend Pay DateDec 02 2025
Days until Ex dividend75 days
Days until Dividend pay date139 days

Does 4507 pay a reliable dividends?

See 4507 dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/16 07:24
End of Day Share Price 2025/07/16 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shionogi & Co., Ltd. is covered by 24 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Aaron HoCFRA Equity Research